Joo Hyun O1, Brandon S Luber2, Jeffrey P Leal1, Hao Wang2, Vanessa Bolejack3, Scott M Schuetze4, Lawrence H Schwartz5, Lee J Helman6, Denise Reinke7, Laurence H Baker4, Richard L Wahl8. 1. Division of Nuclear Medicine, The Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, Maryland. 2. Division of Biostatistics and Bioinformatics, Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland. 3. Cancer Research and Biostatistics, Seattle, Washington. 4. Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan. 5. Department of Radiology, Columbia University, New York, New York. 6. Pediatric Oncology Branch, National Cancer Institute, Bethesda, Maryland; and. 7. SARC, Ann Arbor, Michigan. 8. Division of Nuclear Medicine, The Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, Maryland wahlr@mir.wustl.edu.
Abstract
UNLABELLED: The aim of this study was to assess the prognostic and predictive value of early quantitative (18)F-FDG PET to monitor therapy with an antibody to the insulinlike growth factor 1 receptor (IGF-1R antibody) in patients with Ewing sarcoma family of tumors (ESFT). METHODS: (18)F-FDG PET images at baseline and approximately 9 d after initiation of IGF-1R antibody therapy in 115 patients with refractory or relapsed ESFT were prospectively obtained as part of the Sarcoma Alliance for Research through Collaboration trial. Responses were centrally evaluated by PERCIST 1.0 in 93 patients. The 9-d PET responses were correlated to overall survival (OS), progression-free survival (PFS), and clinical benefit after 6 wk of therapy based on clinical observation and CT response by World Health Organization anatomic criteria. RESULTS: The median OS was 8.1 mo (95% confidence interval, 6.4-10.0 mo). When PERCIST was used, patients with progressive metabolic disease showed shorter OS (median, 4.7 mo) than patients without progression (median, 10.0 mo; P = 0.001). Progressive metabolic disease on day-9 PET was associated with a significantly higher risk of death (hazard ratio, 2.8; 95% confidence interval, 1.5-5.5). Changes in (18)F-FDG uptake after 9 d of therapy had an area under the curve of receiver-operating characteristic of 0.71 to predict 1-y OS. The area under the curve was 0.63 to predict progression at 3 mo and 0.79 to predict clinical benefit after 6 wk of therapy. CONCLUSION: Treatment response by quantitative (18)F-FDG PET assessed by PERCIST 1.0 as early as 9 d into IGF-1R antibody therapy in patients with ESFT can predict the OS, PFS, and clinical response to therapy.
UNLABELLED: The aim of this study was to assess the prognostic and predictive value of early quantitative (18)F-FDG PET to monitor therapy with an antibody to the insulinlike growth factor 1 receptor (IGF-1R antibody) in patients with Ewing sarcoma family of tumors (ESFT). METHODS: (18)F-FDG PET images at baseline and approximately 9 d after initiation of IGF-1R antibody therapy in 115 patients with refractory or relapsed ESFT were prospectively obtained as part of the Sarcoma Alliance for Research through Collaboration trial. Responses were centrally evaluated by PERCIST 1.0 in 93 patients. The 9-d PET responses were correlated to overall survival (OS), progression-free survival (PFS), and clinical benefit after 6 wk of therapy based on clinical observation and CT response by World Health Organization anatomic criteria. RESULTS: The median OS was 8.1 mo (95% confidence interval, 6.4-10.0 mo). When PERCIST was used, patients with progressive metabolic disease showed shorter OS (median, 4.7 mo) than patients without progression (median, 10.0 mo; P = 0.001). Progressive metabolic disease on day-9 PET was associated with a significantly higher risk of death (hazard ratio, 2.8; 95% confidence interval, 1.5-5.5). Changes in (18)F-FDG uptake after 9 d of therapy had an area under the curve of receiver-operating characteristic of 0.71 to predict 1-y OS. The area under the curve was 0.63 to predict progression at 3 mo and 0.79 to predict clinical benefit after 6 wk of therapy. CONCLUSION: Treatment response by quantitative (18)F-FDG PET assessed by PERCIST 1.0 as early as 9 d into IGF-1R antibody therapy in patients with ESFT can predict the OS, PFS, and clinical response to therapy.
Authors: Frederic H Fahey; Paul E Kinahan; Robert K Doot; Mehmet Kocak; Harold Thurston; Tina Young Poussaint Journal: Med Phys Date: 2010-07 Impact factor: 4.071
Authors: Alberto S Pappo; Shreyaskumar R Patel; John Crowley; Denise K Reinke; Klaus-Peter Kuenkele; Sant P Chawla; Guy C Toner; Robert G Maki; Paul A Meyers; Rashmi Chugh; Kristen N Ganjoo; Scott M Schuetze; Heribert Juergens; Michael G Leahy; Birgit Geoerger; Robert S Benjamin; Lee J Helman; Laurence H Baker Journal: J Clin Oncol Date: 2011-10-24 Impact factor: 44.544
Authors: Scott M Schuetze; Brian P Rubin; Cheryl Vernon; Douglas S Hawkins; James D Bruckner; Ernest U Conrad; Janet F Eary Journal: Cancer Date: 2005-01-15 Impact factor: 6.860
Authors: Madhusudan A Savaikar; Timothy Whitehead; Sudipta Roy; Lori Strong; Nicole Fettig; Tina Prmeau; Jingqin Luo; Shunqiang Li; Richard L Wahl; Kooresh I Shoghi Journal: J Nucl Med Date: 2019-11-22 Impact factor: 10.057
Authors: Usama Salem; Behrang Amini; Hubert H Chuang; Najat C Daw; Wei Wei; Tamara Miner Haygood; John E Madewell; Colleen M Costelloe Journal: J Cancer Date: 2017-08-25 Impact factor: 4.207
Authors: Hesham M Amin; Ajaykumar C Morani; Najat C Daw; Salah-Eddine Lamhamedi-Cherradi; Vivek Subbiah; Brian A Menegaz; Deeksha Vishwamitra; Ghazaleh Eskandari; Bhawana George; Robert S Benjamin; Shreyaskumar Patel; Juhee Song; Alexander J Lazar; Wei-Lien Wang; Razelle Kurzrock; Alberto Pappo; Peter M Anderson; Gary K Schwartz; Dejka Araujo; Branko Cuglievan; Ravin Ratan; David McCall; Sana Mohiuddin; John A Livingston; Eric R Molina; Aung Naing; Joseph A Ludwig Journal: Cancers (Basel) Date: 2020-07-02 Impact factor: 6.639
Authors: Charline Lasnon; Elske Quak; Pierre-Yves Le Roux; Philippe Robin; Michael S Hofman; David Bourhis; Jason Callahan; David S Binns; Cédric Desmonts; Pierre-Yves Salaun; Rodney J Hicks; Nicolas Aide Journal: EJNMMI Phys Date: 2017-05-30